Journal ArticleDOI
Improved Graft Survival after Renal Transplantation in the United States, 1988 to 1996
Sundaram Hariharan,Christopher P. Johnson,Barbara A. Bresnahan,S. Taranto,Matthew McIntosh,Donald Stablein +5 more
TLDR
There has been a substantial increase in short-term and long-term survival of kidney grafts from both living and cadaveric donors since 1988.Abstract:
Background The introduction of cyclosporine has resulted in improvement in the short-term outcome of renal transplantation, but its effect on the long-term survival of kidney transplants is not known. Methods We analyzed the influence of demographic characteristics (age, sex, and race), transplant-related variables (living or cadaveric donor, panel-reactive antibody titer, extent of HLA matching, and cold-ischemia time), and post-transplantation variables (presence or absence of acute rejection, delayed graft function, and therapy with mycophenolate mofetil and tacrolimus) on graft survival for all 93,934 renal transplantations performed in the United States between 1988 and 1996. A regression analysis adjusted for these variables was used to estimate the risk of graft failure within the first year and more than one year after transplantation. Results From 1988 to 1996, the one-year survival rate for grafts from living donors increased from 88.8 to 93.9 percent, and the rate for cadaveric grafts increased...read more
Citations
More filters
Journal ArticleDOI
Basiliximab (simulect) for the treatment of steroid-resistant rejection in pediatric liver transpland recipients: a preliminary experience1
Marion M. Aw,Rhiannon Taylor,Anita Verma,A Parke,A Baker,D. Hadzic,Paolo Muiesan,M. Rela,N D Heaton,G. Mieli-Vergani,Anil Dhawan +10 more
TL;DR: Five of seven pediatric liver transplant recipients with SRR experienced successful outcomes with basiliximab treatment without major side effects, indicating that it is a safe alternative to OKT3 and other antilymphocyte antibodies.
Journal ArticleDOI
Impact of acute rejection episodes on long-term graft survival following simultaneous kidney-pancreas transplantation.
K Sudhakar Reddy,Darcy Davies,Debra B. Ormond,Sony Tuteja,Bruce A. Lucas,Thomas D. Johnston,Thomas Waid,John McKeown,Dinesh Ranjan +8 more
TL;DR: It is concluded that acute rejection episodes have a negative impact on the long‐term kidney graft survival in the SKPT population similar to that in the cadaver kidney transplant population.
Journal ArticleDOI
Recipient-related predictors of kidney transplantation outcomes in the elderly.
Parta Hatamizadeh,Miklos Z. Molnar,Miklos Z. Molnar,Miklos Z. Molnar,Elani Streja,Paungpaga Lertdumrongluk,Mahesh Krishnan,Csaba P. Kovesdy,Csaba P. Kovesdy,Kamyar Kalantar-Zadeh +9 more
TL;DR: In this article, the authors compared mortality rates between kidney transplant recipients (KTRs) and the general population across different age categories, and examined patient and allograft survival in 15 667 elderly KTRs (65- 30 kg/m 2 ).
Journal ArticleDOI
Expression of urokinase plasminogen activator and its receptor during acute renal allograft rejection
Joris J. T. H. Roelofs,Ajda T. Rowshani,José G. Van Den Berg,Nike Claessen,Jan Aten,Ineke J. M. ten Berge,Jan J. Weening,Sandrine Florquin +7 more
TL;DR: This study shows that uPA and uPAR are up-regulated during acute renal allograft rejection, uPA levels in urine and serum correlate with serum creatinine levels, and u PA and u PAR are produced by inflammatory cells, tubular epithelium, and vascular endothelium during acute kidney allografted rejection.
Journal ArticleDOI
Should living-unrelated renal transplant recipients receive antibody induction? Results of a clinical experience trial.
A Wiland,Jeffrey C. Fink,Matthew R. Weir,Benjamin Philosophe,Steven A. Blahut,M. Ryan Weir,Beth Copenhaver,Stephen T. Bartlett +7 more
TL;DR: The higher rejection rates in LURT recipients (no induction) compared with cadaveric renal transplant (CRT) recipients (basiliximab induction), despite similar chronic immunosuppression, indicate the potential advantage of anti-CD25 induction in LurT protocols to reduce the risk of acute rejection.
References
More filters
Book ChapterDOI
Nonparametric Estimation from Incomplete Observations
Edward L. Kaplan,Paul Meier +1 more
TL;DR: In this article, the product-limit (PL) estimator was proposed to estimate the proportion of items in the population whose lifetimes would exceed t (in the absence of such losses), without making any assumption about the form of the function P(t).
Journal ArticleDOI
Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group.
TL;DR: This study demonstrated that MMF administered at a dosage of 2 g or 3 g daily, in combination with maintenance CsA and corticosteroids as triple therapy following ATGAM® induction therapy, is more effective than an otherwise identical regimen that includes azathioprine instead of MMF in preventing acute allograft rejection in first cadaveric renal transplant patients.
Journal ArticleDOI
A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group
TL;DR: Tacrolimus is more effective than cyclosporine in preventing acute rejection in cadaveric renal allograft recipients, and significantly reduces the use of antilymphocyte antibody preparations.
Journal ArticleDOI
Risk factors for chronic rejection in renal allograft recipients.
P. S. Almond,A. J. Matas,K. J. Gillingham,David L. Dunn,William D. Payne,Paul F. Gores,Rainer W.G. Gruessner,J. S. Najarian +7 more
TL;DR: In this article, the authors found that acute rejection, CsA dosage < 5 mg/kg/day at 1 year, and infection are the major risk factors for the development of chronic rejection.
Related Papers (5)
The Banff 97 working classification of renal allograft pathology
Lorraine C. Racusen,Kim Solez,Robert B. Colvin,Stephen M. Bonsib,Maria Castro,Tito Cavallo,Byron P. Croker,A. Jake Demetris,Cynthia B. Drachenberg,Agnes B. Fogo,Peter N. Furness,Lillian W. Gaber,Ian W. Gibson,Dennis Glotz,J. Goldberg,Joseph P. Grande,Philip F. Halloran,H.E. Hansen,Barry Hartley,Pekka Hayry,Claire M. Hill,Ernesto O. Hoffman,Lawrence G. Hunsicker,Anne S. Lindblad,Niels Marcussen,M. J. Mihatsch,Tibor Nadasdy,Peter Nickerson,T. Steen Olsen,John C. Papadimitriou,Parmjeet Randhawa,David C. Rayner,Ian S.D. Roberts,Stephen Rose,D. Rush,Luis Salinas-Madrigal,Daniel R. Salomon,Stale Sund,Eero Taskinen,Kiril Trpkov,Yutaka Yamaguchi +40 more